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Abstract
Introduction Gastric acid-related symptoms are highly
prevalent in the general population (21–40%), and more
than 11% of individuals use medication for the treatment of
these symptoms. The uptake of micronutrients is dependent
on the gastrointestinal potential of hydrogen (pH).
Objective We hypothesized that medication affecting
gastrointestinal pH reduces the availability of B vitamins,
thereby deranging one-carbon metabolism and detrimen-
tally affecting spermatogenesis.
Methods This explorative nested case–control study in
men of subfertile couples investigated associations
between medication used for gastric acid-related symptoms
and semen parameters. We included 40 men using medi-
cation for gastric acid-related symptoms and 843 men not
using medication. Semen analyses were performed
between 70 days before and 21 days after the visit.
Results The use of medication was associated with a
twofold higher risk of a low total motile sperm count
[TMSC\1 9 106, odds ratio (OR) 2.090, p = 0.049] and
negatively with sperm concentration (b -0.320,
p = 0.028). Red blood cell folate was positively associated
with TMSC (b 0.257, p = 0.026), sperm count (b 1.679,
p = 0.013) and ejaculate volume (b 0.120, p = 0.023), and
total homocysteine (tHcy) was negatively associated with
sperm count (b -0.077, p = 0.021).
Conclusion Here we delineate associations between the
use of medication for gastric acid-related symptoms and
poor semen quality in men of subfertile couples. The use of
medication for gastric acid-related symptoms is associated
with a twofold higher risk of a low TMSC and a decreased
sperm concentration. Although these findings warrant fur-
ther research on causality, the associations between folate,
tHcy and semen quality emphasize the importance of pre-
conception counselling in male subfertility.
Key Points
Medication used for gastric acid-related symptoms is
associated with low total motile sperm count and
decreased sperm concentration.
More studies are needed to test drug safety of
medication on fertility parameters in men.
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1 Introduction
Around 15% of couples are subfertile—pregnancy not
achieved after 1 year of unprotected intercourse—of which
half remain involuntarily childless [1]. In 45%, the cause
can be attributed to a male factor [2]. To contribute to
future treatment and prevention of male subfertility, it is of
great importance to investigate causes and the underlying
pathophysiology.
In 20–40% of the general population, gastric acid-re-
lated symptoms are present, and in about 11%, medication
is used [3, 4]. However, its impact on semen parameters
has scarcely been studied. Antacids, proton-pump inhibi-
tors (PPIs) and histamine receptor antagonists (H2RAs)
induce a prolonged increase in gastric pH, impairing the
gastrointestinal absorption of nutrients, including folate
and cobalamin, these being essential for spermatogenesis
[5–7]. B vitamin shortages derange one-carbon metabolism
and induce hyper-homocysteinaemia, which causes exces-
sive oxidative stress and interferes with biological pro-
cesses and DNA structures [8].
Seminal plasma folate, cobalamin and total homocys-
teine (tHcy) are associated with the sperm DNA frag-
mentation index and sperm concentration [9, 10]. This is
supported by the detrimental effects of poor nutrition and
beneficial effects of a healthy diet on sperm parameters
[9, 11, 12]. In addition, folic acid and zinc supplements
increase sperm count, concentration and seminal plasma
folate concentration [9, 13, 14].
Therefore this explorative study aims to investigate
whether the use of medication for gastric acid-related
symptoms is associated with semen parameters and
biomarkers of one-carbon metabolism in men of subfertile
couples.
2 Materials and Methods
2.1 Study Design
Between 2007 and 2012, couples contemplating pregnancy
and visiting the outpatient clinic of the Department of
Obstetrics and Gynaecology at the Erasmus MC, Univer-
sity Medical Centre in Rotterdam, the Netherlands, were
offered preconception counselling. These couples were
referred because of subfertility, i.e. when pregnancy is not
achieved after 1 year of unprotected intercourse [1]. Men
were invited to participate in the study and completed a
self-administered questionnaire to obtain data on medica-
tion use (type, dosage and frequency), smoking (yes/no),
use of alcohol (yes/no), recreational drugs (yes/no) and
folic acid supplements (yes/no) (see Electronic
Supplementary Material 1). At the visit, the questionnaires
were verified by a trained counsellor, and height and
weight were measured to calculate body mass index (BMI)
(kg/m2). The information on nutrition and lifestyle was
screened for risk factors, and individual advice on inade-
quacies was given during the visit. Men who provided
written informed consent and a semen analysis between
70 days before and 21 days after the visit were included in
the study. This window was defined because it covers
3 months of spermatogenesis during which medication use
was assessed and reduces confounding by counselling. We
excluded men with semen samples provided by microsur-
gical epididymal sperm aspiration (MESA), percutaneous
epididymal sperm aspiration (PESA) or retrograde ejacu-
lation. Men with incomplete data and men using other
medication for gastric acid-related symptoms were exclu-
ded as well.
2.2 Semen Sample Collection and Analysis
Semen analyses were performed on the clinical indication
of subfertility, and these data were obtained from medical
records. The examination and processing were performed
before 2010 according to the fourth edition of the World
Health Organization (WHO) laboratory manual and after-
wards according to the fifth edition [15, 16]. Men received
a leaflet with instructions on how to provide a semen
sample. The obligatory abstinence period for producing a
semen sample was 3–5 days. The sample had to be col-
lected in a non-toxic plastic container provided by the
laboratory and had to be delivered within 1 h of production
at the outpatient clinic of the Division of Reproductive
Medicine at the Erasmus MC, University Medical Centre,
Rotterdam, The Netherlands. To avoid large changes in
temperature, the semen sample had to be kept at ambient
temperature during transport [17]. After liquefaction the
following sperm parameters were assessed using a Zeiss
microscope (Carl Zeiss, Oberkochen, Germany): ejaculate
volume (normal range [2.0 mL); sperm concentration
(normal range [20 9 106 sperm/mL); and percentage of
motile and immotile spermatozoa (normal range [50%
with grade A ? B motility). Sperm concentration was
determined with an improved Neubauer Hemocytometer
counting chamber. Total sperm count was calculated as the
product of ejaculate volume and sperm concentration.
Sperm motility parameters type A (rapid progressive
motility), type B (slow or sluggish progressive motility),
type C (local motility) and type D (immotility) were
assessed at 37 C. Total motile sperm count (TMSC) was
calculated as the product of ejaculate volume, sperm con-
centration and grade A ? B motility. A TMSC\1 9 106
was defined as low because it represents severe oligoas-
thenoteratozoospermia [18, 19]. All semen analyses were
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performed in one centre and laboratory, which participates
in the external quality control scheme of the Dutch Foun-
dation for Quality Assessment in Clinical Laboratories
(SKML). The staff performing these analyses are trained
and tested annually according to the certified ESHRE
(European Society of Human Reproduction and Embryol-
ogy) course for performing semen analyses.
The laboratory of the Erasmus MC received the certi-
fication of the International Organization for Standardiza-
tion (ISO9001), the international standard for quality
measurement. The between-technician variation for sperm
concentration was 1.6% [intraclass correlation coefficient
(ICC) 0.992, 95% confidence interval (CI) 0.978–0.997].
The between-technician variation for sperm motility was
2.4% (ICC 0.988, 95% CI 0.972–0.996).
2.3 Biomarkers
At the preconception visit, venous blood samples were
drawn in a Vacutainer ethylenediaminetetraacetate
(EDTA) tube for the determination of red blood cell (RBC)
folate and plasma tHcy; for serum folate and cobalamin, a
dry Vacutainer tube (BD diagnostics, Plymouth, UK) was
used. EDTA blood was kept on ice, and plasma was sep-
arated by centrifugation within 1 h for determination of
tHcy. Immediately after blood sampling, 0.1 mL of EDTA
blood was haemolysed with 0.9 mL freshly prepared 1.0%
ascorbic acid. The haematocrit in EDTA blood was
determined on an ADVIA 120 Hematology Analyzer
(Bayer Diagnostics, Leverkusen, Germany). The haemo-
lysate was centrifuged for 5 min at 10009g, after which
folate was measured in the haemolysate. RBC folate was
calculated with the following formula: (nM haemolysate
folate 9 10/haematocrit) - [nM serum folate 9 (1 -
haematocrit)/haematocrit] = nM RBC folate. tHcy was
determined using a sensitive liquid chromatography tan-
dem mass spectrum method (HPLC-Tandem MS, Waters
Micromass Quattro Premier XE Mass Spectrometer with
Acquity UPLC system, Milford, Massachusetts, USA).
Blood obtained in dry Vacutainer tubes was centrifuged at
20009g; serum was collected and, during routine labora-
tory procedures, analysed using an immunoelectrochemi-
luminescence assay (E170; Roche Diagnostics GmbH,
Mannheim, Germany). Inter-assay coefficients of variation
for serum folate were 4.5% at 13 nmol/L and 5.7% at
23 nmol/L; for serum cobalamin, they were 3.6% at
258 pmol/L and 2.2% at 832 pmol/L; and for plasma tHcy,
they were 4.8% at 14.6 lmol/L and 3.3% at 34.2 lmol/L.
2.4 Statistical Analyses
Chi-squared tests and Mann–Whitney U tests were per-
formed to evaluate differences between the groups. To
perform linear and logistic regression analyses, a normal
distribution of the sperm parameters was achieved with
root transformation of ejaculate volume and sperm count,
and fourth root transformation of TMSC and sperm con-
centration. Univariable and multivariable linear and logis-
tic regression models were applied to study associations
between medication use and sperm parameters. For the
univariable linear regression analyses of sperm parameters,
RBC folate was assessed in pmol/L for better interpretation
of the estimate (pmol/L = nmol/L 9 103). Age, ethnicity,
smoking and alcohol use were selected as potential con-
founders based on associations with semen parameters. The
cut-off concentration for serum folate of C22.5 nmol/L
was used to confirm folic acid supplement use [20]. Sta-
tistical analyses were performed using SPSS software for
Windows (version 21.0, IBM SPSS, Statistics for Win-
dows, Armonk, NY, USA; IBM Corp.) with a level of
significance of 0.05.
3 Results
A total of 2255 men visiting the preconception outpatient
clinic were eligible for participation, from whom we
excluded 137 who did not provide written informed con-
sent and 846 who did not provide a semen analysis between
70 days before and 21 days after the visit. From the
remaining 1272 men, we excluded 23 with MESA, PESA
or retrograde ejaculation samples, ten with incomplete
data, 329 using any other medication and 27 without
information on medication use. This resulted in the analysis
of 883 men, of whom 40 used medication for gastric acid-
related symptoms (PPIs n = 34, antacids n = 3, and
H2RAs n = 3), and 843 controls not using any medication.
Of the 40 medication users, the use was daily in 29 men,
weekly in two men and when needed in seven men. This
data was missing in two men. General characteristics of
included (n = 883) and excluded (n = 1235) men of
subfertile couples are presented in Electronic Supplemen-
tary Material 2. All characteristics were comparable
between the groups except a slightly lower age (34 vs.
35 years, p = 0.003) and higher percentage of no medi-
cation use in the study population (95.5 and 52.6% non-
users, p\ 0.001) inherent to the selection. Table 1 shows
the general characteristics of medication users (n = 40)
and controls (n = 843). In medication users, age was sig-
nificantly higher (38 and 34 years, p = 0.002) and alcohol
and drug use was lower than in controls (55 and 71%,
p = 0.031, and 0.0 and 7.7%, p = 0.029, respectively).
Serum and RBC folate tended to be higher and cobalamin
and tHcy tended to be lower in medication users, albeit not
significantly. The abstinence period and time to semen
analysis were comparable between the groups. All sperm
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parameter values were slightly but not significantly lower
in medication users, except for a higher ejaculate volume
(3.4 and 2.8 mL, p = 0.036). Figure 1 depicts the median
values and interquartile ranges of sperm concentration,
TMSC and sperm motility.
Being a Dutch native was associated with a lower sperm
concentration (b -0.128, 95% CI -0.23 to -0.02,
p = 0.016) and a higher ejaculate volume (b 0.126, 95%
CI 0.07–0.18, p\ 0.001). Smoking was negatively asso-
ciated with TMSC (b -0.173, 95% CI -0.30 to -0.05,
p = 0.008), sperm count (b -1.138, 95% CI -1.88 to
-0.40, p = 0.003) and ejaculate volume (b -0.093, 95%
CI -0.15 to -0.04, p = 0.001). Alcohol use was positively
associated with sperm motility (b 2.506, 95% CI
0.26–4.75, p = 0.029), TMSC (b 0.130, 95% CI
0.001–0.26, p = 0.048) and ejaculate volume (b 0.069,
95% CI 0.01–0.13, p = 0.020). Age, BMI, folic acid sup-
plement use and drug use were not significantly associated
with sperm parameters.
Table 2 presents associations between medication for
gastric acid-related symptoms and a decreased sperm
concentration [b -0.311, standard error (SE) 0.144].
Backwards transformation to the original scale resulted in a
decrease in sperm concentration of 10.5 9 106/mL in
medication users. Moreover, a twofold higher risk of low
TMSC was observed in medication users [unadjusted odds
ratio (OR) 2.158, 95% CI 1.05–4.43, p = 0.036]. After
adjustment for smoking, this risk slightly increased (OR
2.161, 95% CI 1.05–4.44, p = 0.036). Additional adjust-
ment for alcohol use, age and ethnicity slightly attenuated
the risk estimate (OR 2.090, 95% CI 1.00–4.35,
p = 0.049). Adjustment of the latter model for the WHO
manual edition did not affect the results (OR 2.148, 95% CI
1.02–4.48, p = 0.042). The multivariable linear regression
analysis showed the same (b -0.323, SE 0.146,
p = 0.027).
Univariable linear regression analyses revealed positive
associations between RBC folate (pmol/L) and TMSC (b
0.257, 95% CI 0.03–0.48, p = 0.026), sperm count (b
1.679, 95% CI 0.35–3.01, p = 0.013) and ejaculate volume
(b 0.120, 95% CI 0.02–0.22, p = 0.023). tHcy was nega-
tively associated with sperm count (b -0.077, 95% CI
-0.14 to -0.01, p = 0.021). Serum folate and cobalamin
were not associated with any sperm parameter.
Table 1 General characteristics of the study population of men of subfertile couples visiting the preconception outpatient clinic
Users of medication for gastric
acid-related symptoms (n = 40)
Controls (n = 843)
Age (years) 38 (34–42)** 34 (30–39)
BMI (kg/m2) 25.9 (23.4–29.3) 26.1 (23.9–28.6)
Ethnicity (Dutch) 24 (60.0 %) 533 (63.5 %)
Previous child (yes) 9 (23.7 %) 157 (19.4 %)
Stress (yes) 5 (15.6 %) 99 (13.1 %)
Smoking (yes) 17 (42.5 %) 281 (33.4 %)
Alcohol (yes) 22 (55.0 %)* 597 (71.0 %)
Recreational drugs (yes) 0 (0.0 %)* 65 (7.7 %)
Folic acid supplement use (yes) 11 (28.9 %) 175 (22.6 %)
Biochemical parameters
Folate (nmol/L) 17.6 (12.6–25.0) 17.2 (13.4–21.8)
RBC folate (nmol/L) 987 (828–1109) 952 (779–1126)
Cobalamin (pmol/L) 279 (240–399) 299 (239–381)
tHcy (lmol/L) 11.0 (9.7–13.5) 11.5 (9.7–13.5)
Sperm parameters
Sperm count (106/ejaculate) 58.6 (8.4–119.6) 66.3 (20.7–147.6)
Ejaculate volume (mL) 3.4 (2.4–4.2)* 2.8 (1.8–3.9)
Sperm concentration (106/mL) 20 (3–46) 26 (9–59)
Sperm motility (A?B %) 32 (11–47) 39 (23–49)
Total motile sperm count (106/ejaculate) 20.3 (0.8–51.3) 25.2 (4.2–68.9)
Abstinence period (days) 4 (3–5) 4 (3–6)
Time to semen analysis (min) 40 (25–55) 45 (30–60)
Values are expressed as median (IQR) or number (%). Chi-squared and Mann–Whitney tests were performed. Normal range biochemical
parameters: folate C8 nmol/L, RBC folate C500 nmol/L, cobalamin C145 pmol/L, tHcy\15 lmol/L
BMI body mass index, IQR interquartile range, RBC folate red blood cell folate, tHcy total homocysteine
* p\ 0.05, ** p\ 0.01
N. A. Huijgen et al.
4 Discussion
This explorative study shows that use of antacids, PPIs and
H2RAs is associated with impaired semen parameters in men
of subfertile couples visiting a tertiary hospital in the
Netherlands. These medication users showed a decreased
sperm concentration and a twofold higher risk of low TMSC.
The strengths of the study are the standardized semen
sample collection and semen analyses in a single and qual-
ified laboratory centre, thereby limiting risks of
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Fig. 1 a Sperm concentration (p = 0.090), b total motile sperm
count (p = 0.209) and c motility (A ? B%) (p = 0.095) in men
using medication for gastric acid-related symptoms (n = 40) and
controls (n = 843). The box plots display the 25th and 75th
percentile, the horizontal line marks the median value, and the
whiskers extend to the minimum and maximum observations that are
within 1.5 times the interquartile range
Table 2 Uni- and multivariable linear regression analyses in men of subfertile couples with a semen analysis performed within an interval of
70 days before and 21 days after the visit (n = 883)
Predictor Ejaculate
volume H(mL)
b (SE)
Sperm
concentration
ﬃ
4
p
(106/mL)
b (SE)
Sperm count
H(106/ejaculate)
b (SE)
Total motile sperm
count
ﬃ
4
p
(106/ejaculate)
b (SE)
Sperm motility
(A ? B%)
b (SE)
Use of medication for gastric
acid-related symptoms
(unadjusted)
0.132 (0.076) -0.311 (0.144)*a -0.624 (1.009) -0.248 (0.171) -5.403 (2.963)
Use of medication for gastric
acid-related symptoms
(model 1)
0.142 (0.075) -0.307 (0.145)* -0.522 (1.008) -0.234 (0.170) -5.301 (2.964)
Use of medication for gastric
acid-related symptoms
(model 2)
0.161 (0.076)* -0.320 (0.145)* -0.504 (1.012) -0.217 (0.172) -4.561 (2.982)
Data depicted as b and SE. The regression coefficient (b) indicates the increase or decrease (-) change per unit of the sperm parameter
Model 1, adjusted for smoking; model 2, adjusted for smoking, alcohol use, age and ethnicity
SE standard error
* p\ 0.05
a Backward transformation to the original scale results in a decrease of 10.5 9 106/mL in the sperm concentration when medication for gastric
acid-related symptoms was used
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methodological and measurements errors. Protocols were
used by trained counsellors for data collection, verification of
medication use in a defined window, and measurements. To
exclude selection bias, we also showed that general charac-
teristics were largely comparable in included and excluded
men. Weaknesses are, firstly, that due to the small sample
sizes, the individual medicines (PPIs, H2RAs and antacids)
could not be evaluated, and, secondly, confounding by
indication, because in all medication users, gastrointestinal
symptoms were present. Although no abnormal semen
parameters were shown in men with digestive diseases, these
issues have to be addressed in future research [21]. Under-
reporting of medication use is an issue to be considered,
because previous research reported that 11% of Dutch men
and women used medication for gastric acid-related symp-
toms, which is much higher than the 5% in our study [3].
Because these medicines are also available over the counter,
a validation through pharmacy databases was not possible.
In addition, frequency of medication use, but not duration
of use, was taken into account, which is a limitation but
compensates the reliability of current use. Therefore this
study can also not assess the—although very unlikely—
harmful pharmacological effects of a single dose on semen
quality. One semen sample of each man was available, which
does not account for intra-individual variation of semen
parameters. Residual confounding by a sedentary lifestyle,
sauna visits, nutritional behaviour or incompleteness of the
sample collection cannot be excluded as well and has to be
addressed in future [22, 23]. Confounding, however, was
reduced by selecting semen samples only in a strictly defined
window that was independent of exposures and bias due to
the exclusion of conditions affecting semen parameters, i.e.
varicoceles or cryptorchidism.
Our findings are supported by Hayashi et al., who reported
that quitting or switching H2RAs improved semen quality
[24]. Others have shown a reduction in sperm viability in a
dose- and time-dependent manner when liquefied semen
samples were exposed to H2RAs [25]. Both ranitidine and
cimetidine were considered to be acting as anti-androgens,
but only the use of cimetidine impaired hypothalamic–pi-
tuitary–gonadal function [26]. Ranitidine, the only H2RA
reported in our study, did not bind to androgen receptors or
influence basal serum concentrations of testosterone,
luteinizing hormone, follicle stimulating hormone or pro-
lactin in fertile men. The mean sperm count decreased during
ranitidine treatment, although this difference was not sig-
nificant [27]. The higher ejaculate volume in medication
users is new and so far cannot be explained by a pharmaco-
logical mechanism of action. Our previous study investi-
gating the effect of the duration of PPIs only on semen
quality substantiates the potential harmful effects observed
in this study. A threefold higher risk of a low TMSC was
observed in men visiting the general practitioner when PPIs
were used between 12 and 6 months preceding semen
analysis, suggesting that a long-term increase in gastric pH
results in a decline of sperm quality [28].
Detrimental effects of BMI, age or alcohol consumption
on semen quality were not observed. This may be due to
the small variation of these conditions and effect estimates
relative to the large variations in sperm parameters. Our
studies and those of others reported that obesity or central
adiposity are associated with impaired sperm motility,
ejaculate volume, sperm concentration, TMSC [29, 30] and
azoospermia or oligozoospermia [31]. The latter study also
reported no differences in sperm concentration across BMI
categories. Age above 60 has been associated with a raised
sperm DNA fragmentation index, but similar to our results,
was not significantly associated with other sperm parame-
ters [32]. The association between alcohol use and semen
parameters is not substantiated by the rather conflicting
literature and is complicated because the majority of men
in this study used alcohol [33–37]. In addition, smoking
negatively influenced TMSC, ejaculate volume and sperm
count, which is in line with the studies of others [38, 39].
From these data, we conclude that differences in general
characteristics of the study populations, sample sizes,
precision of exposure assessment, and the effects at the
extremes of conditions only (BMI[30, excessive alcohol
consumption) might explain the differences in associations
between BMI, age, alcohol use and sperm parameters.
Associations between the biomarkers of one-carbon
metabolism, RBC folate, tHcy and semen quality are in line
with our studies and those of others [9, 10, 40]. Moreover,
these observations are supported by studies demonstrating
associations between folate intake by supplements or food
and semen quality [12, 41]. A traditional Dutch diet is
positively associated with RBC folate and with sperm
concentration, and a diet rich in fruits and vegetables is
negatively associated with seminal plasma tHcy and sperm
DNA fragmentation index [9, 11]. In our study, the slightly
lower cobalamin level in medication users did not differ
significantly from non-users. This may be explained by a
higher percentage of vitamin supplement users in medica-
tion users, resulting in higher serum and RBC folate, albeit
not significantly, and the small sample size. The use of
folic acid supplements was not associated with semen
quality and therefore not included in the multivariable
analyses [9, 12–14]. This is very likely due to the limited
folic acid supplement use in our study.
5 Conclusion
The use of medication for gastric acid-related symptoms is
associated with impaired semen parameters in men of
subfertile couples contemplating pregnancy. These first
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findings have to be interpreted with caution and emphasize
the need for further research on causality and awareness of
potential detrimental effects of medication for gastric acid-
related symptoms on semen quality.
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